216 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28259626	90	Perfluorinated hydroxamic acids are potent and selective inhibitors of HDAC-like enzymes from Pseudomonas aeruginosa.	University of Applied Sciences Darmstadt
27377864	55	Kinetic and structural insights into the binding of histone deacetylase 1 and 2 (HDAC1, 2) inhibitors.	Broad Institute of Mit and Harvard
27186676	186	Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.	West China Hospital of Sichuan University
26890116	30	Biphenyl-4-yl-acrylohydroxamic acids: Identification of a novel indolyl-substituted HDAC inhibitor with antitumor activity.	University of Milan
26819662	13	Potent, Selective, and CNS-Penetrant Tetrasubstituted Cyclopropane Class IIa Histone Deacetylase (HDAC) Inhibitors.	Biofocus
27060764	30	Computer-aided identification of new histone deacetylase 6 selective inhibitor with anti-sepsis activity.	Sungkyunkwan University
26443078	108	Discovery of Selective Histone Deacetylase 6 Inhibitors Using the Quinazoline as the Cap for the Treatment of Cancer.	Sichuan University
26890114	56	Design, synthesis and biological evaluation of bisthiazole-based trifluoromethyl ketone derivatives as potent HDAC inhibitors with improved cellular efficacy.	Shanghai Institute of Materia Medica
26814680	71	Identification of N-(6-mercaptohexyl)-3-(4-pyridyl)-1H-pyrazole-5-carboxamide and its disulfide prodrug as potent histone deacetylase inhibitors with in vitro and in vivo anti-tumor efficacy.	Shenyang Pharmaceutical University
26706171	138	Novel thiol-based histone deacetylase inhibitors bearing 3-phenyl-1H-pyrazole-5-carboxamide scaffold as surface recognition motif: Design, synthesis and SAR study.	Shenyang Pharmaceutical University
26689485	18	Orally available stilbene derivatives as potent HDAC inhibitors with antiproliferative activities and antitumor effects in human tumor xenografts.	Orchid Chemicals & Pharmaceuticals
26753813	22	Design and synthesis of an activity-based protein profiling probe derived from cinnamic hydroxamic acid.	University of Minnesota
26331334	99	Discovery of Novel Class I Histone Deacetylase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.	Guangzhou Institute of Biomedicine and Health
26086931	38	Strategies for the Discovery of Target-Specific or Isoform-Selective Modulators.	Shandong University
26264503	46	Discovery of 1-hydroxypyridine-2-thiones as selective histone deacetylase inhibitors and their potential application for treating leukemia.	University of Minnesota
26287310	87	Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit.	University College London
25637120	94	Evaluation of histone deacetylase inhibitors (HDACi) as therapeutic leads for human African trypanosomiasis (HAT).	St. Jude Children'S Research Hospital
22344701	30	Biocatalytic synthesis and structure elucidation of cyclized metabolites of the deacetylase inhibitor panobinostat (LBH589).	Novartis Institutes For Biomedical Research
25147612	25	Modulation of Activity Profiles for Largazole-Based HDAC Inhibitors through Alteration of Prodrug Properties.	University of Florida
25906087	14	Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor.	Shandong University
25905694	24	Novel histone deacetylase inhibitors induce growth arrest, apoptosis, and differentiation in sarcoma cancer stem cells.	Istituto Ortopedico Rizzoli (Ior)
25022972	24	Bicyclic tetrapeptides as potent HDAC inhibitors: effect of aliphatic loop position and hydrophobicity on inhibitory activity.	University of Rajshahi
24997578	41	Design and synthesis of CHAP31, trapoxin B and HC-toxin based bicyclic tetrapeptides disulfide as potent histone deacetylase inhibitors.	University of Rajshahi
24972008	36	1,3,4-Oxadiazole-containing histone deacetylase inhibitors: anticancer activities in cancer cells.	Sapienza University of Rome
24864038	112	Design and synthesis of novel and highly-active pan-histone deacetylase (pan-HDAC) inhibitors.	Nippon Pharmaceutical Chemicals
25462271	33	Development of 3-hydroxycinnamamide-based HDAC inhibitors with potent in vitro and in vivo anti-tumor activity.	Shandong University
25454270	82	Histone deacetylase inhibitors derived from 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine and related heterocycles selective for the HDAC6 isoform.	TBA
25238284	52	Identification of a novel aminotetralin class of HDAC6 and HDAC8 selective inhibitors.	Roche Pharmaceutical Research and Early Development
25221651	12	Novel antiproliferative chimeric compounds with marked histone deacetylase inhibitory activity.	University of Bologna
25218912	103	Design, synthesis, and biological evaluation of 1, 3-disubstituted-pyrazole derivatives as new class I and IIb histone deacetylase inhibitors.	Chinese Academy of Sciences
24900838	30	Delayed and Prolonged Histone Hyperacetylation with a Selective HDAC1/HDAC2 Inhibitor.	Merck Research Laboratories
24588105	56	Synthesis and evaluation of new Hsp90 inhibitors based on a 1,4,5-trisubstituted 1,2,3-triazole scaffold.	Universit£
24565573	35	4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors.	Universit£
24742384	90	Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors.	Universit£
24694055	35	Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity.	Shandong University
17196388	12	Discovery of uracil-based histone deacetylase inhibitors able to reduce acquired antifungal resistance and trailing growth in Candida albicans.	Sapienza University of Rome
24015327	42	Development of a chimeric c-Src kinase and HDAC inhibitor.	University of Michigan
23368884	80	Potent and selective inhibition of histone deacetylase 6 (HDAC6) does not require a surface-binding motif.	Broad Institute of Mit and Harvard
23252603	35	Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells.	Heinrich Heine Universit£T
23116147	30	Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries.	Kyoto Prefectural University of Medicine
23061376	63	Pharmacokinetic optimization of class-selective histone deacetylase inhibitors and identification of associated candidate predictive biomarkers of hepatocellular carcinoma tumor response.	Roche R & D Center China
23009203	39	Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.	University of Illinois At Chicago
23021104	32	Cyclic tetrapeptides with thioacetate tails or intramolecular disulfide bridge as potent inhibitors of histone deacetylases.	Graduate School of Life Science and Systems Engineering
22642300	160	Design, synthesis, and biological activity of a novel series of human sirtuin-2-selective inhibitors.	Kyoto Prefectural University of Medicine
22541394	30	Appraisal of GABA and PABA as linker: design and synthesis of novel benzamide based histone deacetylase inhibitors.	Guru Ghasidas University
21984958	83	Potential Agents for Treating Cystic Fibrosis: Cyclic Tetrapeptides that Restore Trafficking and Activity of ¿F508-CFTR.	TBA
21874153	54	Effect of Inhibiting Histone Deacetylase with Short-Chain Carboxylic Acids and Their Hydroxamic Acid Analogs on Vertebrate Development and Neuronal Chromatin.	Broad Institute of Harvard and Mit
18809328	64	Optimization of a series of potent and selective ketone histone deacetylase inhibitors.	Irbm/Merck Research Laboratories
17956988	14	Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases.	Istituto Di Ricerche Di Biologia Molecolare
18397826	18	Evaluation of antiangiogenic activity of azumamides by the in vitro vascular organization model using mouse induced pluripotent stem (iPS) cells.	Waseda University
18381238	4	Novel uracil-based 2-aminoanilide and 2-aminoanilide-like derivatives: histone deacetylase inhibition and in-cell activities.	Sapienza University of Rome
18182289	127	Exploration of the internal cavity of histone deacetylase (HDAC) with selective HDAC1/HDAC2 inhibitors (SHI-1:2).	Merck Research Laboratories
18247554	134	Histone deacetylase inhibitors: from bench to clinic.	Menarini Ricerche
16987657	45	A series of novel, potent, and selective histone deacetylase inhibitors.	Irbm/Merck Research Laboratories
15454224	15	Novel histone deacetylase inhibitors: cyclic tetrapeptide with trifluoromethyl and pentafluoroethyl ketones.	Crest Research Project
14613312	106	Histone deacetylase inhibitors.	Aton Pharma
14584932	23	Discovery of (aryloxopropenyl)pyrrolyl hydroxyamides as selective inhibitors of class IIa histone deacetylase homologue HD1-A.	Sapienza University of Rome
21417419	5	Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.	Dac
21548582	57	Design, synthesis, docking, and biological evaluation of novel diazide-containing isoxazole- and pyrazole-based histone deacetylase probes.	University of Illinois At Chicago
21875805	5	Synthesis of a new trifluoromethylketone analogue of l-arginine and contrasting inhibitory activity against human arginase I and histone deacetylase 8.	Drexel University
21793558	39	Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities.	University of Wisconsin-Milwaukee
21634430	218	Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.	S*Bio
21712146	20	Synthesis and evaluation of aliphatic-chain hydroxamates capped with osthole derivatives as histone deacetylase inhibitors.	Taipei Medical University
21696956	243	A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold.	Broad Institute of Harvard and Mit
21417297	220	Oxime amides as a novel zinc binding group in histone deacetylase inhibitors: synthesis, biological activity, and computational evaluation.	Universita` Degli Studi Di Siena
21256006	11	Structure and property based design, synthesis and biological evaluation of¿-lactam based HDAC inhibitors.	Yonsei University
21073160	143	Non-Natural Macrocyclic Inhibitors of Histone Deacetylases: Design, Synthesis, and Activity	TBA
19966789	40	Reduced histone deacetylase 7 activity restores function to misfolded CFTR in cystic fibrosis.	The Scripps Research Institute
20491440	12	Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues.	Universidade De Vigo
20451378	107	Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity.	S*Bio
20381359	17	Synthesis and biological activity of cyclotetrapeptide analogues of the natural HDAC inhibitor FR235222.	Universit£
20205394	44	Conformational refinement of hydroxamate-based histone deacetylase inhibitors and exploration of 3-piperidin-3-ylindole analogues of dacinostat (LAQ824).	Novartis Institutes For Biomedical Research
20045316	18	Bicyclic peptides as potent inhibitors of histone deacetylases: optimization of alkyl loop length.	Graduate School of Life Science and Systems Engineering
20143778	70	Discovery of 7-(4-(3-ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer.	Curis
19906529	22	Identification of a series of substituted 2-piperazinyl-5-pyrimidylhydroxamic acids as potent histone deacetylase inhibitors.	Ortho-Biotech Oncology Research & Development
19822426	4	Novel N-hydroxybenzamide-based HDAC inhibitors with branched CAP group.	China Pharmaceutical University
19699639	58	Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors.	Methylgene
19359173	51	Exploring bis-(indolyl)methane moiety as an alternative and innovative CAP group in the design of histone deacetylase (HDAC) inhibitors.	Sigma-Tau Research and Development
19410459	33	Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.	Irbm/Merck Research Laboratories
19285395	66	N-Hydroxy-(4-oxime)-cinnamide: a versatile scaffold for the synthesis of novel histone deacetylase [correction of deacetilase] (HDAC) inhibitors.	R&D Sigma-Tau
19268585	30	Exploring the pharmacokinetic properties of phosphorus-containing selective HDAC 1 and 2 inhibitors (SHI-1:2).	Merck Research Laboratories
19181524	46	N-Hydroxy-1,2-disubstituted-1H-benzimidazol-5-yl acrylamides as novel histone deacetylase inhibitors: design, synthesis, SAR studies, and in vivo antitumor activity.	S*Bio
18951790	109	SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).	Merck Research Laboratories
18930398	117	2-Trifluoroacetylthiophene oxadiazoles as potent and selective class II human histone deacetylase inhibitors.	Irbm-Merck Research Laboratories Rome
18701301	38	Design, synthesis and biological evaluation of novel compounds with conjugated structure as anti-tumor agents.	China Pharmaceutical University
18672316	41	Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR.	Institute of Organic Synthesis
18060775	67	Optimization of biaryl Selective HDAC1&2 Inhibitors (SHI-1:2).	Merck Research Laboratories
17900911	21	Interaction of aliphatic cap group in inhibition of histone deacetylases by cyclic tetrapeptides.	Graduate School of Life Science and Systems Engineering
17881232	42	Molecular design of histone deacetylase inhibitors by aromatic ring shifting in chlamydocin framework.	Graduate School of Life Science and Systems Engineering
17588744	18	Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.	The University of Tokyo
17447750	4	Bispyridinium dienes: histone deacetylase inhibitors with selective activities.	Universidade De Vigo
16884291	12	Highly potent and selective histone deacetylase 6 inhibitors designed based on a small-molecular substrate.	Nagoya City University
16137884	6	Design and synthesis of phthalimide-type histone deacetylase inhibitors.	The University of Tokyo Yayoi
32787077	23	Discovery of Potent Small-Molecule SIRT6 Activators: Structure-Activity Relationship and Anti-Pancreatic Ductal Adenocarcinoma Activity.	Sichuan University
32676157	102	Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.	Merck
32631504	29	Discovery of 5-(4-methylpiperazin-1-yl)-2-nitroaniline derivatives as a new class of SIRT6 inhibitors.	Sichuan University
32672458	164	Characterization of Conformationally Constrained Benzanilide Scaffolds for Potent and Selective HDAC8 Targeting.	University of Toronto Mississauga
32435414	24	Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells.	Sapienza University of Rome
32435375	22	New Dual CK2/HDAC1 Inhibitors with Nanomolar Inhibitory Activity against Both Enzymes.	Universidad San Pablo-Ceu
31787463	67	Novel alkoxyamide-based histone deacetylase inhibitors reverse cisplatin resistance in chemoresistant cancer cells.	Heinrich-Heine-Universit£T D£Sseldorf
27774131	32	Development of a Potent and Selective HDAC8 Inhibitor.	Boston University
27614919	66	Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.	University of Connecticut
30597327	32	A novel class of anthraquinone-based HDAC6 inhibitors.	Keimyung University
30245394	363	HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors.	Indian Csir-Central Drug Research Institute
30629434	64	Discovery of Novel Dual Histone Deacetylase and Mammalian Target of Rapamycin Target Inhibitors as a Promising Strategy for Cancer Therapy.	TBA
31630054	335	Synthesis and structure activity relationship of 1, 3-benzo-thiazine-2-thiones as selective HDAC8 inhibitors.	University of Applied Sciences
32212730	206	Design, Synthesis, and Biological Evaluation of Quinazolin-4-one-Based Hydroxamic Acids as Dual PI3K/HDAC Inhibitors.	National Center For Advancing Translational Sciences
30735902	69	Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides.	Jadavpur University
31431326	63	Novel ?,?-unsaturated hydroxamic acid derivatives overcome cisplatin resistance.	Heinrich-Heine-University D£Sseldorf
31223439	25	Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling.	Umr Cnrs 7285
31938464	93	Class I/IIb-Selective HDAC Inhibitor Exhibits Oral Bioavailability and Therapeutic Efficacy in Acute Myeloid Leukemia.	University of Toronto Mississauga
31655430	56	N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-? induced PD-L1 expression.	Taipei Medical University
31561937	32	Recent advances in class IIa histone deacetylases research.	Heinrich-Heine-Universit£T D£Sseldorf
31177073	22	Discovery of 1,2,4-oxadiazole-Containing hydroxamic acid derivatives as histone deacetylase inhibitors potential application in cancer therapy.	Sichuan University and Collaborative Innovation Center of Biotherapy
31855601	73	Synthesis and in Vitro and in Vivo Biological Evaluation of Tissue-Specific Bisthiazole Histone Deacetylase (HDAC) Inhibitors.	Chinese Academy of Sciences
31414801	84	Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.	University of Illinois At Chicago
32321249	138	Design of Hydrazide-Bearing HDACIs Based on Panobinostat and Their p53 and FLT3-ITD Dependency in Antileukemia Activity.	Ocean University of China
32267687	37	Discovery of Peptide Boronate Derivatives as Histone Deacetylase and Proteasome Dual Inhibitors for Overcoming Bortezomib Resistance of Multiple Myeloma.	Shandong University
32153186	118	Discovery of Thieno[2,3-	Sichuan University and Collaborative Innovation Center of Biotherapy
30418766	35	Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.	Qingdao University
31762274	122	Synthesis of Peptoid-Based Class I-Selective Histone Deacetylase Inhibitors with Chemosensitizing Properties.	Heinrich-Heine-Universit£T D£Sseldorf
30448419	74	Highly fluorescent and HDAC6 selective scriptaid analogues.	Deakin University
30366254	49	Identification of novel quinazoline derivatives as potent antiplasmodial agents.	Universit£
31050421	48	Overview of Recent Strategic Advances in Medicinal Chemistry.	Shandong University
31271281	9	Development of Multifunctional Histone Deacetylase 6 Degraders with Potent Antimyeloma Activity.	Institute of Biotechnology of The Czech Academy of Sciences
31117517	103	Design, Synthesis, and Biological Evaluation of 4-Methyl Quinazoline Derivatives as Anticancer Agents Simultaneously Targeting Phosphoinositide 3-Kinases and Histone Deacetylases.	TBA
30463802	54	Development and characterization of a CNS-penetrant benzhydryl hydroxamic acid class IIa histone deacetylase inhibitor.	Charles River Discovery (Previously Biofocus)
31413795	57	Design, Synthesis, and Biological Evaluation of 2,4-Imidazolinedione Derivatives as HDAC6 Isoform-Selective Inhibitors.	Shandong University
23997923	21	Discovery and activity profiling of thailandepsins A through F, potent histone deacetylase inhibitors, from	University of Wisconsin-Milwaukee
24164245	11	Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp.	University of Connecticut
23820574	89	Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).	China Pharmaceutical University
24900734	9	Histone Deacetylase 4 (HDAC4) Inhibitors: A Promising Treatment for Huntington's Disease.	Therachem Research Medilab (India)
24900743	86	Tropolones as lead-like natural products: the development of potent and selective histone deacetylase inhibitors.	University of Connecticut
29738953	34	Design and biological evaluation of tetrahydro-?-carboline derivatives as highly potent histone deacetylase 6 (HDAC6) inhibitors.	University of Regensburg
29150335	13	Camptothecin-psammaplin A hybrids as topoisomerase I and HDAC dual-action inhibitors.	Universit£
30122227	113	Squaramides as novel class I and IIB histone deacetylase inhibitors for topical treatment of cutaneous t-cell lymphoma.	Nestle Skin Health R&D
29549837	151	Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.	University of Navarra
29505935	13	Indole in the target-based design of anticancer agents: A versatile scaffold with diverse mechanisms.	Mazandaran University of Medical Sciences
29396364	16	Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.	Minia University
29348808	35	Dual NAMPT/HDAC Inhibitors as a New Strategy for Multitargeting Antitumor Drug Discovery.	Second Military Medical University
29259737	10	Novel Polyamine-Naphthalene Diimide Conjugates Targeting Histone Deacetylases and DNA for Cancer Phenotype Reprogramming.	Alma Mater Studiorum-University of Bologna
29223096	45	Discovery of aliphatic-chain hydroxamates containing indole derivatives with potent class I histone deacetylase inhibitory activities.	Taipei Medical University
29776742	55	Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.	Forma Therapeutics
28368585	18	Exploring Derivatives of Quinazoline Alkaloid l-Vasicine as Cap Groups in the Design and Biological Mechanistic Evaluation of Novel Antitumor Histone Deacetylase Inhibitors.	Csir-Indian Institute of Integrative Medicine
29589441	78	Marbostat-100 Defines a New Class of Potent and Selective Antiinflammatory and Antirheumatic Histone Deacetylase 6 Inhibitors.	University of Regensburg
27886544	46	3-Aroylindoles display antitumor activity in vitro and in vivo: Effects of N1-substituents on biological activity.	Taipei Medical University
28771357	50	Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD).	Universit£
28453994	118	Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.	Ghent University
28549219	30	Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.	Novartis Institutes For Biomedical Research
29304284	59	(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo.	Taipei Medical University
29499113	77	Class I HDAC Inhibitors Display Different Antitumor Mechanism in Leukemia and Prostatic Cancer Cells Depending on Their p53 Status.	Medical University of South Carolina
28415009	51	Selective HDAC inhibitors with potent oral activity against leukemia and colorectal cancer: Design, structure-activity relationship and anti-tumor activity study.	Shandong University
28395150	30	4-Indolyl-N-hydroxyphenylacrylamides as potent HDAC class I and IIB inhibitors in vitro and in vivo.	Taipei Medical University (Tmu)
28885834	80	Small Molecule Inhibitors Simultaneously Targeting Cancer Metabolism and Epigenetics: Discovery of Novel Nicotinamide Phosphoribosyltransferase (NAMPT) and Histone Deacetylase (HDAC) Dual Inhibitors.	Second Military Medical University
28581289	20	Alkoxyurea-Based Histone Deacetylase Inhibitors Increase Cisplatin Potency in Chemoresistant Cancer Cell Lines.	Heinrich-Heine-Universit£T D£Sseldorf
14500743	60	Carbamoylcholine homologs: novel and potent agonists at neuronal nicotinic acetylcholine receptors.	The Danish University of Pharmaceutical Sciences
1586393	43	Localization and function of the D3 dopamine receptor.	U. 109
1554381	19	Agonist activity of 2- and 5'-substituted adenosine analogs and their N6-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to adenylate cyclase.	National Institutes of Diabetes and Digestive and Kidney Diseases
1501121	12	Biochemical and pharmacological properties of SR 46349B, a new potent and selective 5-hydroxytryptamine2 receptor antagonist.	Sanofi Recherche
282646	50	Histamine H1 receptors identified in mammalian brain membranes with [3H]mepyramine.	TBA
17825569	48	The influence of modifications in imide fragment structure on 5-HT(1A) and 5-HT(7) receptor affinity and in vivo pharmacological properties of some new 1-(m-trifluoromethylphenyl)piperazines.	Polish Academy of Sciences
17218638	21	Characterization of a potent and selective small-molecule inhibitor of the PIM1 kinase.	Loma Linda University
16455247	15	Pyridone derivatives as potent and selective VLA-4 integrin antagonists.	Glaxosmithkline
10530956	45	Structure-activity relationship of HIV-1 protease inhibitors containing alpha-hydroxy-beta-amino acids. Detailed study of P1 site.	Sankyo